Bioventus (NASDAQ:BVS) Trading Down 6.3% – Time to Sell?

Bioventus Inc. (NASDAQ:BVS)’s share price dropped 6.3% on Thursday . The company traded as low as $9.91 and last traded at $10.2530. Approximately 90,046 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 382,108 shares. The stock had previously closed at $10.94.

Wall Street Analysts Forecast Growth

BVS has been the topic of a number of recent analyst reports. Craig Hallum increased their price objective on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Barrington Research increased their price objective on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. CJS Securities initiated coverage on shares of Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective on the stock. Finally, Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Bioventus currently has a consensus rating of “Buy” and a consensus target price of $14.00.

Bioventus Trading Down 11.1%

The firm has a market capitalization of $812.43 million, a PE ratio of 23.63, a price-to-earnings-growth ratio of 1.36 and a beta of 0.72. The stock’s 50-day moving average price is $9.64 and its 200 day moving average price is $8.45. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13.

Bioventus (NASDAQ:BVS) last issued its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $132.09 million for the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts expect that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Insider Activity

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 33.00% of the company’s stock.

Hedge Funds Weigh In On Bioventus

A number of hedge funds and other institutional investors have recently modified their holdings of BVS. Nantahala Capital Management LLC boosted its stake in shares of Bioventus by 28.0% during the second quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company’s stock valued at $34,959,000 after purchasing an additional 1,155,192 shares in the last quarter. Hillsdale Investment Management Inc. boosted its stake in shares of Bioventus by 148.7% during the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after purchasing an additional 401,230 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in shares of Bioventus during the fourth quarter valued at approximately $2,886,000. Kent Lake PR LLC bought a new position in shares of Bioventus during the second quarter valued at approximately $2,317,000. Finally, Kennedy Capital Management LLC boosted its stake in shares of Bioventus by 219.6% during the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company’s stock valued at $3,088,000 after purchasing an additional 317,157 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.